Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca antibody cocktail study shows success treating COVID-19

10/11/2021 | 02:52am EST

* Shortly after infection, drug cuts risk of deterioration

* Astra sees shot's main use in preventative setting

* Faces competition from other antibodies, Merck tablet (Adds quotes from media call)

Oct 11 (Reuters) - AstraZeneca's antibody cocktail against COVID-19, which has proven to work as a preventative shot in the non-infected, was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.

The drug, a combination of two antibodies called AZD7442, reduced the risk of severe COVID-19 or death by 50% in non-hospitalised patients who have had symptoms for seven days or less, the Anglo-Swedish drugmaker said on Monday.

The risk reduction was even better in patients who started therapy within just five days of initial symptoms, but AstraZeneca joins an already crowded field of medicines that were shown to prevent deterioration in patients with mild disease when given soon after diagnosis.

AstraZeneca executive Mene Pangalos said in a media call that the treatment results would mainly underscore the potential future use as a non-vaccine prevention.

"If and when this is approved it will be used in the treatment setting as well. But the real differentiator for this antibody is going to be in the prophylactic setting," he said.

Similar therapies made with a class of drugs called monoclonal antibodies are being developed by Regeneron, Eli Lilly and GlaxoSmithKline with partner Vir . These therapies are approved for emergency use in the United States for treating mild-to-moderate COVID-19.

Regeneron's therapy showed 72% protection against symptomatic infection in the first week, and 93% after that.

GSK-Vir's showed a 79% reduction in the risk of hospitalisation or death due to any cause, while Eli Lilly's therapy showed a 70% reduction in viral load at day seven compared to a placebo.

Merck & Co Inc, in turn, is emphasising the convenience of use of its anti-COVID-19 tablet, which cut the risk of having to got to hospital or of dying by 50% in a trial of early-stage patients who had at least one risk factor.

Merck, collaborating with Ridgeback Biotherapeutics, on Monday applied for U.S. emergency clearance for the oral drug.

AstraZeneca, whose COVID-19 vaccine has been widely used across the globe, asked U.S. regulators last week to grant emergency use authorisation for AZD7442 as a preventative shot.

As such, it is designed to protect people who do not have a strong enough immune response to vaccines, primarily those who have received organ transplants or who are in cancer care.

If full market clearance is obtained after any emergency approval the market could widen, for instance, to include crew and passengers of a cruise ship, said Pangalos.

"You can say the same for people who don't want to be vaccinated but want an antibody," he added.

AstraZeneca said it is submitting the new treatment data on AZD7442 to global health regulators.

The trial took place across 13 countries and involved more than 900 adult participants, 90% of whom suffered from conditions that made the particularly vulnerable to COVID-19, such as cancer and diabetes. One half receiving AZD7442 and the rest a placebo.

Full trial results will be submitted for publication in a peer-reviewed journal, AstraZeneca said.

AZD7442 contains laboratory-made antibodies designed to linger in the body for months to contain the virus in case of an infection. A vaccine, in contrast, relies on an intact immune system to develop targeted antibodies and infection-fighting cells.

While Monday's results cover the use of AZD7442 in non-hospitalised patients, a separate trial is also studying its use as a treatment for hospitalised COVID-19 patients. (Reporting by Ludwig Burger in Frankfurt, Yadarisa Shabong in Bengaluru; Editing by Saumyadeb Chakrabarty, Kirsten Donovan and Alexander Smith)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.67% 8223 Delayed Quote.14.19%
GLAXOSMITHKLINE PLC 1.48% 1577.8 Delayed Quote.15.86%
REGENERON PHARMACEUTICALS 1.61% 635.09 Delayed Quote.31.46%
VIR BIOTECHNOLOGY, INC. 11.96% 42.98 Delayed Quote.60.49%
All news about ASTRAZENECA PLC
12:39pFTSE 100 Closes Up Amid Rise in Chinese Demand for Commodities
DJ
12:14pAstraZeneca's Drug Candidate Shows Durable Tumor Response in Triple Negative Breast Can..
MT
12:12pAstraZeneca and Ionis Sign Deal to Develop and Commercialize Eplontersen, AZN to Pay IO..
MT
11:20aEuropean ADRs Move Sharply Higher in Tuesday Trading
MT
11:17aUp to 1 million COVID vaccines wasted in Nigeria last month
RE
11:16aUp to 1 million COVID vaccines wasted in Nigeria last month
RE
10:26aM&A market remains strong despite decline in activity
AQ
08:49aJefferies Lowers AstraZeneca to Hold from Buy, Cuts PT
MT
07:47aFTSE Gains, Glaxo Seen With Further Upside From Consumer Healthcare Spinoff
DJ
07:45aMarketScreener's World Press Review - December 7, 2021
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 926 M - -
Net income 2021 2 724 M - -
Net Debt 2021 24 888 M - -
P/E ratio 2021 41,0x
Yield 2021 2,54%
Capitalization 169 B 168 B -
EV / Sales 2021 5,40x
EV / Sales 2022 4,41x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 110,91 $
Average target price 137,02 $
Spread / Average Target 23,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC14.19%171 675
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321